目的：评价依匹哌唑治疗精神分裂症的疗效和安全性。方法系统检索2015年11月以前关于依匹哌唑治疗精神分裂症的随机对照试验，最终根据纳入标准纳入3项文献进行meta分析，效应指标包括依匹哌唑治疗前后的阳性与阴性症状量表、临床疗效总评量表评分差值及不良反应例数。结果精神分裂症患者服用依匹哌唑治疗6周后，阳性与阴性症状量表总分、阳性症状、阴性症状因子分及临床疗效总评量表总分均较治疗前显著下降；且不同剂量组对这些评分的贡献量差异有显著性（ P＜0．05或0．01）。结论依匹哌唑治疗精神分裂症患者疗效显著，在改善阴性症状方面具有优势，安全性高。“,”Objective To evaluate the efficacy and safety of brexpiprazole in the treatment of schizophreni‐a .Methods Randomized controlled trials of brexpiprazole in the treatment of schizophrenia before novem‐ber 2015 were systematically searched ,meta‐analyses conducted for 3 literatures meeting the inclusion cri‐teria ,and effect indicators consisted of the score differences of the Positive and Negative Syndrome Scale (PANSS) and Clinical Global Impression (CGI) and numbers of adverse events before and after brexpi‐prazole treatment .Results After 6 week brexpiprazole treatment ,the total ,positive and negative symp‐tom score of the PANSS and the total score of the CGI lowered more significantly compares with pretreat‐ment ;there were significant differences in contributions of different dosages to these scores (P<0 .05 or 0 .01) .Conclusion Brexpiprazole has an evident effect in the treatment of schizophrenia ,an advantage in improving negative symptoms and higher safety .